Flexible marginal structural models for estimating the cumulative effect of a time-dependent treatment on the hazard: Reassessing the cardiovascular risks of didanosine treatment in the Swiss HIV Cohort study

Journal of the American Statistical Association

Volumn 109, Issue 506, 2014, Pages 455-464

  Xiao, Yongling ^a   Abrahamowicz, Michal ^b   Moodie, Erica E M ^b   Weber, Rainer ^c   Young, James ^d  

^a Analysis Group Inc   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antiretroviral treatment; Cardiovascular disease; Regression splines; Survival analysis

Indexed keywords

EID: 84987790076     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.2013.872650     Document Type: Article

References (44)

1. Abrahamowicz, M., Bartlett, G., Tamblyn, R., and du Berger, R. (2006), “Modeling Cumulative Dose and Exposure Duration Provided Insights Regarding Associations Between Benzodiazepines and Injuries,” Journal of Clinical Epidemiology, 59, 393–403.
2. Abrahamowicz, M., Beauchamp, M., and Sylvestre, M. (2012), “Comparison of Alternative Models for Linking Drug Exposure With Adverse Effects,” Statistics in Medicine, 31, 1014–1030.
3. Abrahamowicz, M., and MacKenzie, T. (2007), “Joint Estimation of Time- Dependent and Non-Linear Effects of Continuous Covariates on Survival,” Statistics in Medicine, 26, 392–408.
4. Abrahamowicz, M., MacKenzie, T., and Esdaile, J. (1996), “Time-Dependent Hazard Ratio:Modeling and Hypothesis TestingWith Application in Lupus Nephritis,” Journal of the American Statistical Association, 91, 1432–1439.
5. Abrahamowicz, M., and Tamblyn, R. (2005), “Drug Utilization Patterns,” in Encyclopedia of Biostatistics (2nd ed.), eds. P. Armitage and T. Colton, New York: Wiley, pp. 1533–1553.
6. Arenas-Pinto, A., Bhaskaran, K., Dunn, D., and Weller, I. (2008), “The Risk of Developing Peripheral Neuropathy Induced by Nucleoside Reverse Transcriptase Inhibitors Decreases Over Time: Evidence From the Delta Trial,” Antiviral Therapy, 13, 289–295.
7. Bavinger, C., Bendavid, E., Niehaus, K., Olshen, R. A., Olkin, I., Sundaram, V., Wein, N., Holodniy, M., Hou, N., Owens, D. K., et al. (2013), “Risk of Cardiovascular Disease From Antiretroviral Therapy for HIV: A Systematic Review,” PLoS One, 8, e59551, 1–14.
8. Brookhart, M. A., Wang, P., Solomon, D. H., and Schneeweiss, S. (2006), “Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable,” Epidemiology (Cambridge, Mass.), 17, 268–275.
9. Brumback, B. A., Hernán, M. A., Haneuse, S. J., and Robins, J. M. (2004), “Sensitivity Analyses for Unmeasured Confounding Assuming a Marginal Structural Model for Repeated Measures,” Statistics in Medicine, 23, 749–767.
10. Carr, A., and Amin, J. (2009), “Efficacy and Tolerability of Initial Antiretroviral Therapy: A Systematic Review,” AIDS, 23, 343–353.
11. Chowers, M., Gottesman, B.-S., Leibovici, L., Schapiro, J., and Paul, M. (2010), “Nucleoside Reverse Transcriptase Inhibitors in Combination Therapy for HIV Patients: Systematic Review and Meta-Analysis,” European Journal of Clinical Microbiology & Infectious Diseases, 29, 779–786.
12. Cole, S., and Hernán, M. (2008), “Constructing Inverse Probability Weights for Marginal Structural Models,” American Journal of Epidemiology, 168, 656–664.
13. Csajka, C., and Verotta, D. (2006), “Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives,” Journal of Pharmacokinetics and Pharmacodynamics, 33, 227–279.
14. Dixon, W., Abrahamowicz, M., Beauchamp, M., Ray, D., Bernatsky, S., Suissa, S., and Sylvestre, M. (2012), “Immediate and Delayed Impact of Oral Glucocorticoid Therapy on Risk of Serious Infection in Older PatientsWith Rheumatoid Arthritis: A Nested Case–Control Analysis,” Annals of the Rheumatic Diseases, 71, 1128–1133.
15. Ghosh, S., Chandran, A., and Jansen, J. P. (2012), “Epidemiology of HIVRelated Neuropathy: A Systematic Literature Review,” AIDS Research and Human Retroviruses, 28, 36–48.
16. Hernán, M., Brumback, B., and Robins, J. (2000), “Marginal StructuralModels to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men,” Epidemiology, 11, 561–570.
17. Hernán, M., Cole, S., Margolick, J., Cohen, M., and Robins, J. (2005), “Structural Accelerated Failure Time Models for Survival Analysis in Studies With Time-Varying Treatments,” Pharmacoepidemiology and Drug Safety, 14, 477–492.
18. Hernández, D., Muriel, A., Abraira, V., Pérez, G., Porrini, E., Marrero, D., Zamora, J., González-Posada, J., Delgado, P., Rufino, M., and Torres, A. (2012), “Renin–Angiotensin System Blockade and Kidney Transplantation: Longitudinal Cohort Study,” Nephrology Dialysis Transplantation, 21, 417–422.
19. Kuehl, M., and Stevens, M. J. (2012), “Cardiovascular Autonomic Neuropathies as Complications of Diabetes Mellitus,” Nature Reviews Endocrinology, 8, 405–416.
20. Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Boccara, F., and Costagliola, D. (2010), “Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients: A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4,” Archives of Internal Medicine, 170, 1228–1238.
21. Lundgren, J., Neuhaus, J., Babiker, A., Cooper, D., Duprez, D., El-Sadr, W., Emery, S., Gordin, F., Kowalska, J., Phillips, A., Prineas, R. J., Reiss, P., Sabin, C., Tracy, R., Weber, R., Grund, B., and Neaton, J. D. (2008a), “Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIV-Infected Patients,” AIDS, 22, F17–F24.
22. Lundgren, J., Neuhaus, J., Babiker, A., Cooper, D., Duprez, D., El-Sadr, W., Emery, S., Gordin, F., Kowalska, J., Phillips, A., Prineas, R. J., Reiss, P., Sabin, C., Tracy, R., Weber, R., Grund, B., and Neaton, J. D. (2008b), “Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels During Follow-Up,” The Journal of Infectious Diseases, 197, 1145–1155.
23. Martínez, E., Larrousse, M., and Gatell, J. M. (2009), “Cardiovascular Disease and HIV Infection: Host, Virus, or Drugs?” Current Opinion in Infectious Diseases, 22, 28–34.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents (accessed October 2013), “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
25. Platt, R. W., Brookhart, M. A., Cole, S. R., Westreich, D., and Schisterman, E. F. (2013), “An Information Criterion for Marginal Structural Models,” Statistics in Medicine, 32, 1383–1393.
26. Ramsay, J. (1988), “Monotone Regression Splines in Action,” Statistical Science, 3, 425–441.
27. Robins, J. (1999), “Marginal Structural Models Versus StructuralNested Models as Tools for Causal Inference,” Statistical Models in Epidemiology: The Environment and Clinical Trials, 116, 95–134.
28. Robins, J., and Hernán, M. (2008), “Estimation of the Causal Effects of Time- Varying Exposures,” in Longitudinal Data Analysis, eds. G. Fitzmaurice, M. Davidian, G. Verbekeet al., New York: Taylor & Francis, pp. 553–599.
29. Robins, J., Hernán, M., and Brumback, B. (2000), “Marginal Structural Models and Causal Inference in Epidemiology,” Epidemiology, 11, 550–560.
30. Sabin, C., Worm, S., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., DeWit, S., Law, M., D’ArminioMonforte, A., Friis-Møller, N., Kirk, O., Pradier, C., Weller, I., Phillips, A. and Lundgren, J. (2008), “Use of Nucleoside Reverse Transcriptase Inhibitors and Risk of Myocardial Infarction in HIV-Infected Patients Enrolled in the D:A:D Study: AMulti-Cohort Collaboration,” Lancet, 371, 1417–1426.
31. Sackoff, J., Hanna, D., Pfeiffer, M., and Torian, L. (2006), “Causes of Death Among Persons With AIDS in the Era of Highly Active Antiretroviral Therapy: New York City,” Annals of Internal Medicine, 145, 397–406.
32. Schwarz, G. (1978), “Estimating the Dimension of a Model,” The Annals of Statistics, 6, 461–464.
33. Stanford University, HIV Drug Resistance Database. (2007), “Antiretroviral Drug Summary: Didanosine (DDI; Videx),” available at http://hivdb.stanford.edu/pages/GRIP/ddI.html.
34. Swiss HIVCohort Study (2010), “Cohort Profile: The Swiss HIVCohort Study,” International Journal of Epidemiology, 39, 1179–1189.
35. Sylvestre, M., and Abrahamowicz, M. (2009), “Flexible Modeling of the Cumulative Effects of Time-Dependent Exposures on the Hazard,” Statistics in Medicine, 28, 3437–3453.
36. Sylvestre, M., Abrahamowicz, M., Capek, R., and Tamblyn, R. (2011), “Assessing the Cumulative Effects of Exposure to Selected Benzodiazepines on the Risk of Fall-Related Injuries in the Elderly,” International Psychogeriatrics, 1, 1–10.
37. Volinsky, C., and Raftery, A. (2000), “Bayesian Information Criterion for Censored Survival Models,” Biometrics, 56, 256–262.
38. Walker, A. (1996), “Confounding by Indication,” Epidemiology, 7, 335–336.
39. Wegman, E., and Wright, I. (1983), “Splines in Statistics,” Journal of the American Statistical Association, 78, 351–365.
40. Westreich, D., Cole, S., Tien, P., Chmiel, J., Kingsley, L., Funk, M., Anastos, K., and Jacobson, L. (2010), “Time Scale and Adjusted Survival Curves for Marginal Structural Cox Models,” American Journal of Epidemiology, 171, 691–700.
41. Worm, S., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A., Friis-Møller, N., Kirk, O., Fontas, E., Weller, I., Phillips, A., and Lundgren, J. (2010), “Risk of Myocardial Infarction in Patients With HIV Infection Exposed to Specific Individual Antiretroviral Drugs From the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study,” Journal of Infectious Diseases, 201, 318–330.
42. Xiao, Y., Moodie, E., and Abrahamowicz, M. (2012), “Comparison of Approaches to Weight Truncation for Marginal Structural Cox Models,” Epidemiologic Methods, 2, 1–20.
43. Young, J., Hernán, M., Picciotto, S., and Robins, J. (2010), “Relation Between Three Classes of Structural Models for the Effect of a Time-Varying Exposure on Survival,” Lifetime Data Analysis, 16, 71–84.
44. Young, J., Klein, M. B., and Ledergerber, B. (2011), “Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis,” Clinical Infectious Diseases, 52, 154–155.